Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
22C3 antibody
SP263 antibody
immunocytochemistry
immunohistochemistry
non-small cell lung carcinoma
programmed cell death-ligand 1
tissue fixation
Journal
Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
28
09
2020
received:
20
08
2020
accepted:
30
09
2020
pubmed:
28
10
2020
medline:
27
7
2021
entrez:
27
10
2020
Statut:
ppublish
Résumé
Immunohistochemical staining of programmed death-ligand 1 (PD-L1) is used to determine which patients with non-small cell lung cancer (NSCLC) may benefit most from immunotherapy. Therapeutic management of many patients with NSCLC is based on cytology instead of histology. In this study, concordance of PD-L1 immunostaining between cytology cell blocks and their histologic counterparts was analyzed. Furthermore, the effect of various fixatives and fixation times on PD-L1 immunoreactivity was studied. Paired histologic and cytologic samples from 67 patients with NSCLC were collected by performing fine-needle aspiration on pneumonectomy/lobectomy specimens. Formalin-fixed, agar-based or CytoLyt/PreservCyt-fixed Cellient cell blocks were prepared. Sections from cell blocks and tissue blocks were stained with SP263 (standardized assay) and 22C3 (laboratory-developed test) antibodies. PD-L1 scores were compared between histology and cytology. In addition, immunostaining was compared between PD-L1-expressing human cell lines fixed in various fixatives at increasing increments in fixation duration. Agar cell blocks and tissue blocks showed substantial agreement (κ = 0.70 and κ = 0.67, respectively), whereas fair-to-moderate agreement was found between Cellient cell blocks and histology (κ = 0.28 and κ = 0.49, respectively). Cell lines fixed in various alcohol-based fixatives showed less PD-L1 immunoreactivity compared with those fixed in formalin. In contrast to SP263, additional formalin fixation after alcohol fixation resulted in preserved staining intensity using the 22C3 laboratory-developed test and the 22C3 pharmDx assay. Performing PD-L1 staining on cytologic specimens fixed in alcohol-based fixatives could result in false-negative immunostaining results, whereas fixation in formalin leads to higher and more histology-concordant PD-L1 immunostaining. The deleterious effect of alcohol fixation could be reversed to some degree by postfixation in formalin.
Sections du résumé
BACKGROUND
Immunohistochemical staining of programmed death-ligand 1 (PD-L1) is used to determine which patients with non-small cell lung cancer (NSCLC) may benefit most from immunotherapy. Therapeutic management of many patients with NSCLC is based on cytology instead of histology. In this study, concordance of PD-L1 immunostaining between cytology cell blocks and their histologic counterparts was analyzed. Furthermore, the effect of various fixatives and fixation times on PD-L1 immunoreactivity was studied.
METHODS
Paired histologic and cytologic samples from 67 patients with NSCLC were collected by performing fine-needle aspiration on pneumonectomy/lobectomy specimens. Formalin-fixed, agar-based or CytoLyt/PreservCyt-fixed Cellient cell blocks were prepared. Sections from cell blocks and tissue blocks were stained with SP263 (standardized assay) and 22C3 (laboratory-developed test) antibodies. PD-L1 scores were compared between histology and cytology. In addition, immunostaining was compared between PD-L1-expressing human cell lines fixed in various fixatives at increasing increments in fixation duration.
RESULTS
Agar cell blocks and tissue blocks showed substantial agreement (κ = 0.70 and κ = 0.67, respectively), whereas fair-to-moderate agreement was found between Cellient cell blocks and histology (κ = 0.28 and κ = 0.49, respectively). Cell lines fixed in various alcohol-based fixatives showed less PD-L1 immunoreactivity compared with those fixed in formalin. In contrast to SP263, additional formalin fixation after alcohol fixation resulted in preserved staining intensity using the 22C3 laboratory-developed test and the 22C3 pharmDx assay.
CONCLUSIONS
Performing PD-L1 staining on cytologic specimens fixed in alcohol-based fixatives could result in false-negative immunostaining results, whereas fixation in formalin leads to higher and more histology-concordant PD-L1 immunostaining. The deleterious effect of alcohol fixation could be reversed to some degree by postfixation in formalin.
Identifiants
pubmed: 33108706
doi: 10.1002/cncy.22383
pmc: PMC8246726
doi:
Substances chimiques
B7-H1 Antigen
0
Formaldehyde
1HG84L3525
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
304-317Informations de copyright
© 2020 The Authors. Cancer Cytopathology published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
Appl Immunohistochem Mol Morphol. 2015 Apr;23(4):297-302
pubmed: 25265430
Mod Pathol. 2020 Apr;33(4):518-530
pubmed: 31558782
Cancer Cytopathol. 2019 Oct;127(10):643-649
pubmed: 31398281
Cancer Cytopathol. 2018 May;126(5):342-352
pubmed: 29499101
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Virchows Arch. 2012 Sep;461(3):259-69
pubmed: 22814649
Cancer Cytopathol. 2018 Apr;126(4):253-263
pubmed: 29405663
Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):228-35
pubmed: 10981876
J Am Soc Cytopathol. 2018 May-Jun;7(3):133-141
pubmed: 29713584
Cancer Cell. 2019 Aug 12;36(2):168-178.e4
pubmed: 31327656
J Thorac Dis. 2018 Jul;10(Suppl 18):S2127-S2129
pubmed: 30123540
Diagn Pathol. 2016 May 18;11(1):44
pubmed: 27189072
APMIS. 2015 Feb;123(2):108-15
pubmed: 25421919
Histopathology. 2019 Jan;74(2):362-364
pubmed: 30019344
Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):107-113
pubmed: 29084060
Cancer Cytopathol. 2020 Feb;128(2):100-106
pubmed: 31851430
Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):453-459
pubmed: 28549039
Oncogene. 2009 Aug;28 Suppl 1:S14-23
pubmed: 19680292
Clin Transl Sci. 2017 Mar;10(2):84-92
pubmed: 28121072
Cancer Cytopathol. 2013 Jul;121(7):344-53
pubmed: 23408720
Clin Lung Cancer. 2017 Sep;18(5):527-534.e1
pubmed: 28111119
Arch Pathol Lab Med. 2008 Mar;132(3):373-83
pubmed: 18318580
Ann Oncol. 2018 Jun 1;29(6):1417-1422
pubmed: 29659668
Vet Pathol. 2005 Jul;42(4):405-26
pubmed: 16006601
J Pathol Transl Med. 2015 Jul;49(4):300-9
pubmed: 26076721
Cancer Cytopathol. 2021 Apr;129(4):304-317
pubmed: 33108706
Ann Oncol. 2019 May;30(5):863-870
pubmed: 31987360
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Am J Clin Pathol. 2019 Mar 1;151(4):403-415
pubmed: 30534975
Cytopathology. 2018 Dec;29(6):505-524
pubmed: 30153355
Trends Cancer. 2016 Dec;2(12):706-712
pubmed: 28741518
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Cancer Cytopathol. 2018 Apr;126(4):264-274
pubmed: 29411536
Ann Oncol. 2018 Apr 1;29(4):953-958
pubmed: 29351573
Cancer Cytopathol. 2016 Feb;124(2):89-100
pubmed: 26882197